Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | SOAT1 | P35610 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868372 | 0.83 | SOAT1 (0.57) | SOAT1ALDH1A1 | |
| SCHEMBL4872038 | 0.76 | MMP1 (0.46) | MAPTTP53L3MBTL1GAAMEN1 | |
| SCHEMBL4872048 | 0.76 | MMP1 (0.46) | MAPTTP53L3MBTL1GAAMEN1 | |
| SCHEMBL5476317 | 0.71 | OPRM1 (0.69) | OPRM1OPRD1OPRK1OPRL1MAPT | |
| SCHEMBL4877793 | 0.70 | OPRM1 (0.72) | OPRM1OPRD1OPRK1OPRL1MAPT | |
| SCHEMBL4871634 | 0.69 | OPRM1 (0.60) | OPRM1OPRD1OPRK1OPRL1MAPT | |
| SCHEMBL4887076 | 0.69 | MMP1 (0.46) | OPRM1OPRL1MAPTGAAMEN1 | |
| SCHEMBL4887085 | 0.69 | MMP1 (0.46) | OPRM1OPRL1MAPTGAAMEN1 | |
| SCHEMBL4876619 | 0.69 | ALDH1A1 (0.41) | OPRM1OPRD1OPRK1OPRL1MAPT | |
| SCHEMBL4876613 | 0.69 | ALDH1A1 (0.41) | OPRM1OPRD1OPRK1OPRL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080096922-A1 | Novel Sulfonamide derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| EP-1736467-A1 | NOVEL SULFONAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096922-A1 | Novel Sulfonamide derivative | NR4A1, NR4A2, NR4A3 | OPRM1 1290/4885OPRD1 628/4885OPRK1 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.